Clinical Trial Update: A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-02-15